Health Trials

About this trial

The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA. The primary questions it aims to answer are:

* Will UDCA reduce the incidence of glucose intolerance in participants taking oral statins? * Will the use of UDCA decrease other adverse events in patients taking oral statins?

Participants will:

* Take Atorvastatin combined with UDCA or a placebo daily for 6 months * Have follow-up visits on day 40, day 110, and day 180 Have their examination indicators recorded.

Eligibility criteria

Qualifiers

Age 18-75 years old.

LDL-C≥3.4mmol/l (130 mg/dL).

Glycosylated hemoglobin ≤ 6.0% (42 mmol/mol).

Voluntarily sign informed consent.

Disqualifiers

Previous diagnosis of diabetes or prediabetes.

Past or current use of hypoglycemic drugs.

Oral administration of statin lipid-lowering drugs within three months before enrollment.

Combined oral drug quantity ≥3.

Trial design

Treatments tested in this trial

  • Ursodeoxycholic acid (UDCA) 500 mg
  • Placebo

Treatment groups

128 Participants
are divided into 2 treatment groups

Locations

2
Department of Cardiology, First Affiliated Hospital of Xi'an Jiaotong University710061, Xi'anShaanxi, China
The First Affiliated Hospital of Xi 'an Jiaotong University Xi'an China

Sponsors and collaborators

First Affiliated Hospital Xi'an Jiaotong University

Lead sponsor

Source ClinicalTrials.gov